Influx HealthtechNSE:INFLUX +2.49%21 Net Margin % is 13.15% as of Mar. 2026, which is 17% above its 10-year median of 11.23. GuruFocus rates NSE:INFLUX with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Influx Healthtech ranks better than 76.02% on this metric.
The historical rank and industry rank for Influx Healthtech's Net Margin % or its related term are showing as below:
NSE:INFLUX'
s Net Margin % Range Over the Past 10 Years
Min: 7.53 Med: 11.23 Max: 13.99
Current: 13.99
NSE:INFLUX's Net Margin % is ranked better than 76.02% of 955
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs NSE:INFLUX: 13.99
Influx Healthtech (NSE:INFLUX) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Influx Healthtech Net Margin % Related Terms
Influx Healthtech Net Margin % Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Influx Healthtech (NSE:INFLUX) has a Net Margin % of 13.15% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Influx Healthtech and its competitors. This is 17% above median its historical median of 11.23. Over the past decade, Influx Healthtech's Net Margin % has ranged from 7.53 to 13.99. According to the industry distribution chart, Influx Healthtech ranks #229 out of 955 companies in the Drug Manufacturers industry, placing it in the top 24%.
Is Influx Healthtech's Net Margin % too high?
Influx Healthtech's current Net Margin % of 13.15% is 17% above median its 10-year median of 11.23. Over the past 10 years, this metric has ranged from a low of 7.53 to a high of 13.99. The Drug Manufacturers industry median Net Margin % is 5.69. Influx Healthtech's value of 13.15% is 131.1% above this industry median. Based on the distribution chart, Influx Healthtech ranks #229 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Influx Healthtech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #229 out of 955 companies for Net Margin %. This places Influx Healthtech in the top 24% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.69. Influx Healthtech's value of 13.15% is 131.1% above this benchmark. Historically, Influx Healthtech's own Net Margin % has ranged from 7.53 to 13.99 over the past decade. While the company's 10-year median is 11.23 vs. the industry median of 5.69, Influx Healthtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current Net Margin % of 13.15% is 131.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current Net Margin % is 13.15%, which is 17% above median its own 10-year median of 11.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current Net Margin % of 13.15%. The current Net Margin % is 13.15%, which is 17% above median its 10-year median of 11.23 and 131.1% above the Drug Manufacturers industry median of 5.69. Influx Healthtech's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current Net Margin % is 13.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
21GF Score
Get the complete analysis for NSE:INFLUX
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 